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Abstract 
Objective: This is the final report of a phase III randomized study to evaluate the 
role of whole-brain radiotherapy (WBRT) in primary therapy of primary CNS 
lymphoma (PCNSL) after a median follow-up of 81.2 months. 
Methods: Patients with newly diagnosed PCNSL were randomized to high-dose 
methotrexate (HDMTX) - based chemotherapy (CHT) followed by WBRT or 
chemotherapy (CHT) alone. We hypothesized that the omission of WBRT from first-
line treatment would not compromise overall survival (OS; primary endpoint), using a 
non-inferiority design with a margin of 0.9. 
Results: Of 410 patients who entered the post-HDMTX phase (intention-to-treat, ITT 
population) 320 were treated per-protocol (PP). In the PP-population, there was a 
non significant prolongation of progression-free survival (PFS) with WBRT: median 
18.2 versus 11.9 months, HR 0.83 (95%CI 0.65-1.06), p=0.14, and a significant 
prolongation of PFS from last HDMTX: 25.5 versus 12.0 months, HR 0.65 (95% CI 
0.5-0.83), p=0.001, but no OS prolongation: 35.6 versus 37.1 months, HR 1.03 
(95%CI 0.79-1.35), p=0.82. The results in the ITT population were similar to those in 
the PP population with prolongation by WBRT of both PFS: 15.4 versus 9.9 months, 
HR 0.79 (95% CI 0.64-0.98), p=0.034, and PFS from last HDMTX: 19.4 versus 11.9 
months, HR 0.72 (95% CI 0.58-0.89), p=0.003, but not of OS: 32.4 versus 36.1 
months, HR 0.98 (95%CI 0.79-1.26), p=0.98.   
Conclusion: Although the statistical proof of non-inferiority regarding OS was not 
given our results suggest no worsening of OS without WBRT in primary therapy of 
PCNSL.  
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Classification of evidence: This study provides Class I evidence that WBRT can be 
omitted in primary treatment of PCNSL.  
 
 - 6 - Korfel et al.   
 6
Introduction 
Standards of care have not been well defined for primary CNS lymphoma (PCNSL). 
High-dose methotrexate (HDMTX) is the only undisputed standard of care whereas 
the addition of whole-brain radiotherapy (WBRT) has been increasingly questioned 
because of the high frequency of late neurotoxicity after combined modality 
treatment. In 1999, the German PCNSL Study Group (G-PCNSL-SG) had designed 
a prospective, randomized trial to test the hypothesis that primary HDMTX-based 
chemotherapy (CHT) alone was not inferior to primary CHT followed by WBRT for 
immunocompetent patients with newly diagnosed PCNSL. The 2010 report of overall 
survival (OS; the primary endpoint) at a median follow-up of 31.8 months had 
resulted in the conclusion that WBRT can be omitted from first-line treatment of 
PCNSL without compromising OS although non-inferiority had not been formally 
proven.1 Here, we present updated and final data including a new “as-treated” 
analysis after a median follow-up of 81.2 months.  
 
Patients and Methods 
Standard Protocol Approvals, Registrations, and Patient Consents  
The study was approved by the local Human Investigations Committee, and 
informed consent was obtained from each participant. The study is registered with 
ClinicalTrials.gov, number NCT00153530. 
 
Study Design, Selection of Participants and Interventions 
The G-PCNSL-SG1 included immunocompetent patients with newly diagnosed 
PCNSL.1 After 1:1 randomization performed at study enrolment all patients were to 
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receive HDMTX from 1999-2007 and HDMTX plus ifosfamide thereafter. Patients 
achieving complete response (CR) received consolidating WBRT or no further 
treatment, whereas patients without CR received WBRT or second-line CHT with 
high-dose cytarabine (HD-Ara-C). 
 
Study Endpoints and Statistical Analysis 
The goal of the trial was to demonstrate that the omission of WBRT from first-line 
treatment does not compromise OS as the primary endpoint using a non-inferiority 
design with a margin of 0.9. OS was measured from the time of randomization until 
death; progression-free survival (PFS) was measured until progression or death. 
Further, to better assess the role of therapy administered after HDMTX-based CHT 
(HD-Ara-C or WBRT), an additional PFS calculation was performed from the time of 
last HDMTX-based CHT to progression or death per response group (CR versus 
partial remission (PR), stable disease (SD) and progressive disease (PD) pooled) 
herein referred to as PFS from last HDMTX. Additionally, we analysed the ITT 
population by the treatment that was actually given (“as-treated”) e.g. patients 
randomized to WBRT who did not receive WBRT (and received second-line CHT 
instead or no further therapy) were analyzed as no WBRT and patients randomized 
to no WBRT who received WBRT were analyzed as WBRT. As the consequence, 
patients with CR after HDMTX-based CHT were divided in two groups: WBRT and 
no WBRT (= no further therapy) whereas non-CR patients were divided in three 
groups: WBRT, CHT and no therapy (patients who were left with PR, SD or PD after 
HDMTX-based CHT without any further therapy). Multivariate analysis was 
performed by using the Cox proportional hazard model. All hazard ratios refer to the 
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comparison of WBRT vs. no WBRT i.e. hazard ratios lower than 1 are in favour of 
WBRT. 
 
Results 
From 1999-2009, 551 patients (median age: 63 years) were enrolled; of those, 524 
fulfilled the eligibility criteria and started HDMTX-based primary CHT (primary 
eligibility population), 410 entered the post-HDMTX phase with a known response 
status (ITT population) and 320 were treated as randomized (PP population)1 (Fig 
1). The median follow up was 81.2 months.  
In the PP population, there was a non significant PFS prolongation with WBRT: 
median 18.2 versus 11.9 months, HR 0.83 (95% CI 0.65-1.06), p=0.14, and a 
significant prolongation of PFS from last HDMTX: 25.5 versus 12.0 months, HR 0.65 
(95% CI 0.5-0.83), p=0.001. In contrast, early WBRT did not prolong OS: 35.6 
versus 37.1 months, HR 1.03 (95%CI 0.79-1.35), p=0.82.  
When CR and non-CR patients were considered separately, any potential positive 
impact of WBRT was more prominent in non-CR patients. In CR patients, a non-
significant prolongation of PFS and PFS from last HDMTX were found with WBRT: 
42.5 versus 22.3 months, HR 0.69 (95% CI 0.46-1.03), p=0.065; and 40.1 versus 
19.1 months, HR 0.68 (95% CI 0.46-1.01), p=0.057, respectively. There was no 
difference in OS: 44.2 versus 59.0 months, HR 1.06 (95% CI 0.69-1.63), p=0.78. In 
non-CR patients, both PFS and PFS from last HDMTX were prolonged with WBRT: 
5.0 versus 2.9 months, HR 0.6 (95% CI 0.43-0.83), p=0.002; and 16.1 versus 2.9 
months, HR 0.41 (95% CI 0.29-0.57), p<0.001; respectively, whereas no difference 
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in OS was found: 27.4 versus 18.2 months, HR 0.76 (95% CI 0.54-1.08), p=0.119 
(Fig 2A). 
The results in the ITT population were similar to those in the PP population with 
prolongation by WBRT of both PFS: 15.4 versus 9.9 months, HR 0.79 (95% CI 0.64-
0.98), p=0.034, and PFS from last HDMTX: 19.4 versus 11.9 months, HR 0.72 (95% 
CI 0.58-0.89), p=0.003, but not of OS: 32.4 versus 36.1 months, HR 0.98 (95% CI 
0.79-1.26), p=0.98. In CR patients, no differences in PFS, PFS from last HDMTX 
and OS were found: 29.9 versus 25.7 months, HR 0.85 (95% CI 0.6-1.2), p=0.35; 
27.8 versus 23.4 months, HR 0.84 (95% CI 0.6-1.19), p=0.33 and 51.3 versus 61.0 
months, HR 1.13 (95% CI 0.77-1.66), p=0.53, respectively. In non-CR patients there 
was a prolongation of both PFS: 4.7 versus 2.9 months, HR 0.67 (95% CI 0.51-0.89), 
p=0.004, and PFS from last HDMTX: 15.5 versus 5.7 months, HR 0.58 (95% CI 
0.44-0.77), p<0.001 with WBRT, but no difference in OS: 20.7 versus 18.6 months, 
HR 0.86 (95% CI 0.64-1.16), p=0.32, (Fig 2B).  
Multivariate analysis revealed lower Karnofsky performance score (KPS) as a risk 
factor for PFS in both the PP and the ITT population. For PFS from last HDMTX, 
besides lower KPS, not having received WBRT was a risk factor. For OS, higher age 
and lower KPS were risk factors in the PP and the ITT population, whereas male 
gender was a risk factor only in the PP, but not in the ITT population (Suppl Table).  
Results of the “as-treated” analysis supported the observations made in the PP and 
ITT populations (Fig 3). In CR patients PFS from last HDMTX was 33.8 months with 
WBRT and 19.0 months without; HR 0.64 (95% CI 0.44-0.94), p=0.025 and OS 51.9 
versus 59.0 months, HR 0.93 (95% CI 0.68-1.53), p=0.95. In non-CR patients PFS 
from last HDMTX was 15.9 months with WBRT, 3.2 months with CHT and 8.9 
 - 10 - Korfel et al.   
 10
months without further therapy, HR 0.47 (95% CI 0.35-0.62), p<0.001; OS was 23.8, 
14.8 and 27.5 months, respectively, HR 0.76 (95% CI 0.56-1.02), p=0.172, 
respectively.  
 
Discussion 
Long-term results of the G-PCNSL-SG1 trial suggest that there is no significant 
difference in OS when WBRT is omitted from the first-line treatment of PCNSL. Yet, 
the primary hypothesis of non-inferiority according to the study protocol which asked 
for a lower confidence limit of 0.9 was not proven. There was, however, a significant 
PFS prolongation with WBRT both in the PP and ITT population (in the PP population 
of PFS from last HDMTX only), which was most prominent in non-CR patients.  
G-PCNSL-SG-1 may thus define a role of WBRT for disease control in PCNSL. 
WBRT was more effective than HD-Ara-C in patients with disease less- or insensitive 
to HDMTX. This did not translate into a significant OS benefit with only a trend 
towards longer OS in non-CR patients, most probably because of the effectiveness 
of other salvage treatments. However, the study was not powered to detect 
differences in CR and non-CR patients evaluated separately. Compromised PFS, but 
not OS by deferring WBRT has also been observed in two recent retrospective 
analyses.2,3  
Late neurotoxicity is the principal reason to withhold WBRT from initial therapy of 
PCNSL. In the G-PCNSL-SG1 trial clinical and radiologic signs of late neurotoxicity 
were found more frequently in patients after WBRT.1 This is in accordance with the 
results of a retrospective analysis which identified WBRT as the only factor 
significantly associated with late neurotoxicity.4 Moreover, in two recent analyses 
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using detailed neuropsychologic testing more cognitive dysfunction was observed 
with HDMTX-based CHT plus WBRT than with CHT alone.5,6 Although elderly 
patients are considered at particular risk7, clinically manifest late neurotoxicity was 
also found in >20% of younger patients after combined CHT/WBRT8,9 and even in 
63% of patients when extensive neuropsychological assessment was used.10 
Whether reduced-dose WBRT is save or necessary for improved outcome or both11 
requires a randomized trial such as RTOG 1114 (NCT 01399372).  
Based on our results, WBRT can be postponed until relapse in patients with CR to 
HDMTX-based CHT in younger patients. Conversely, in patients aged 60 years or 
older who are at increased risk of both late neurotoxicity and relapse12, alternative 
strategies of CR consolidation must be explored. 
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Figure legends 
 
Figure 1 Trial profile (CONSORT flow diagram) 
Study arm WBRT: Two additional patients were excluded during HDMTX-based 
CHT (one with spinal lymphoma, now classified as “did not meet inclusion 
criteria” and one who refused CHT continuation in two-week intervals, now 
classified as “refused participation”). For one patient the documentation of 6th 
HDMTX course and CR achievement was obtained, and he was reclassified as 
“ITT, with CR, no further treatment”. One patient was reclassified by the treating 
physician as having CR and moved from “ITT, without CR, had no further 
therapy” to “”ITT, CR, refused to receive WBRT”. 
Study arm no WBRT: One patient was wrongly classified as “lost to follow-up 
during first-line CHT“, although he died within four weeks after last HDMTX, and 
is now classified as “died during first-line CHT”. In two patients documentation of 
second-line therapy with HD-Ara-C was obtained, and they were moved from 
“did not receive HD-Ara-C” to “received HD-Ara-C”. In one patient remission 
status (SD) was changed after review of all scans to CR by the treating 
physician, and he was moved from “ITT, without CR, received WBRT” to “ITT, 
with CR, received WBRT”. 
Abbreviations: CHT = chemotherapy, CR = complete response; HD-Ara-C = 
high-dose cytarabine; ITT = intent-to-treat; PP = per–protocol; SD = stable 
disease; WBRT = whole-brain radiotherapy. 
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Figure 2 OS according to the remission status (CR versus non-CR) after HDMTX -
based CHT (A) PP population. (B) ITT population.  
Abbreviations: CHT = chemotherapy; CR = complete response; HDMTX = high-dose 
methotrexate; ITT = intent-to-treat population; PP = per-protocol population, WBRT = 
whole-brain radiotherapy. 
 
Figure 3 PFS from last HDMTX-based CHT and OS analysed as-treated in the ITT 
population. (A) PFS from last HDMTX-based CHT in patients with CR. (B) PFS from 
last HDMTX-based CHT in patients without CR. (C) OS in patients with CR. (D) OS 
in patients without CR. The good outcome of the non-CR patients without further 
treatment can be explained by the fact that six of them most probably did in fact have 
CR after HDMTX–based CHT: they were documented as having CR upon follow-up 
without further therapy. Moreover, one additional patient received WBRT without 
progression six months after HDMTX–based CHT.  
Abbreviations: CHT = chemotherapy; CR = complete response; HDMTX = high-dose 
methotrexate; ITT = intent-to-treat population; PFS = progression-free survival; 
WBRT = whole-brain radiotherapy. 
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31 refused to receive WBRT 8 had no further therapy  
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96 had no further treatment
97 with CR:
1 received WBRT
Figure 1 Trial profile (CONSORT flow diagram)
Study arm WBRT: Two additional patients were excluded during HDMTX-based CHT (one with spinal lymphoma, now 
classified as “did not meet inclusion criteria” and one who refused CHT continuation in two-week intervals, now 
classified as “refused participation”). For one patient the documentation of 6th HDMTX course and CR achievement 
was obtained, and he was reclassified as “ITT, with CR, no further treatment”. One patient was reclassified by the 
treating physician as having CR and moved from “ITT, without CR, had no further therapy” to “”ITT, CR, refused to 
receive WBRT”.
Study arm no WBRT: One patient was wrongly classified as “lost to follow-up during first-line CHT“, although he died 
within four weeks after last HDMTX, and is now classified as “died during first-line CHT”. In two patients documentation 
of second-line therapy with HD-Ara-C was obtained, and they were moved from “did not receive HD-Ara-C” to “received 
HD-Ara-C”. In one patient remission status (SD) was changed after review of all scans to CR by the treating physician, 
and he was moved from “ITT, without CR, received WBRT” to “ITT, with CR, received WBRT”.
Abbreviations: CHT = chemotherapy, CR = complete response; HD-Ara-C = high-dose cytarabine; ITT = intent-to-treat; 
PP = per–protocol; SD = stable disease; WBRT = whole-brain radiotherapy.
CR, no WBRT
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Figure 2 OS according to the remission status (CR versus non-CR) after HDMTX-based CHT (A) PP population. (B) ITT 
population. 
Abbreviations: CHT = chemotherapy; CR = complete response; HDMTX = high-dose methotrexate; ITT = intent-to-treat population; 
PP = per-protocol population, WBRT = whole-brain radiotherapy.
Figure 3 PFS from last HDMTX-based CHT and OS analysed as-treated in the ITT population. (A) PFS from last HDMTX-based 
CHT in patients with CR. (B) PFS from last HDMTX-based CHT in patients without CR. (C) OS in patients with CR. (D) OS in 
patients without CR. 
no therapy
WBRT
no therapy
CHT
Time (months)
Time (months)
WBRTA B
C D
no therapy
WBRT
no therapy
WBRT
CHT
57 51 43 33 26 19 16 13 8 3 1 0 0
127 114 89 69 50 37 21 16 13 10 6 1 0
Number at risk
CR, WBRT
CR, no therapy
130 74 51 39 26 15 14 11 8 2 1 1 0
17 5 4 2 1 1 1 1 0 0 0 0 0
79 19 9 8 5 3 2 2 1 0 0 0 0
57 47 35 26 22 17 13 11 6 3 0 0 0
127 78 56 37 27 18 11 9 6 5 2 1 0
Number at risk
CR, WBRT
CR, no therapy
Number at risk
non-CR, WBRT
non-CR, no therapy
non-CR, CHT
130 84 62 51 37 22 17 15 9 2 1 1 0
17 13 8 6 4 1 1 1 0 0 0 0 0
79 43 29 22 16 9 5 4 1 0 0 0 0
Number at risk
non-CR, WBRT
non-CR, no therapy
non-CR, CHT
HR 0.64 (95% CI 0.44-0.94), p=0.025 HR 0.47 (95% CI 0.35-0.62), p<0.001 
HR 0.93 (95% CI 0.68-1.53), p=0.95 HR 0.76 (95% CI 0.56-1.02), p=0.172
The good outcome of the non-CR patients without further treatment can be explained by the fact that six of them most 
probably did in fact have CR after HDMTX–based CHT: they were documented as having CR upon follow-up without further 
therapy. Moreover, one additional patient received WBRT without progression six months after HDMTX–based CHT. 
Abbreviations: CHT = chemotherapy; CR = complete response; PFS = progression-free survival; HDMTX = high-dose 
methotrexate; ITT = intent-to-treat population; WBRT = whole-brain radiotherapy.
